Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
August 05, 2020 17:01 ET
|
Novartis International AG
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1...
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
June 29, 2020 02:45 ET
|
Novartis International AG
Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for...
Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
June 02, 2020 16:05 ET
|
Novartis International AG
Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics License...
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
May 27, 2020 16:30 ET
|
Denali Therapeutics Inc.
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
May 27, 2020 01:15 ET
|
Novartis International AG
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no...
Using Neuroscience to Evaluate and Guide Treatment for Pediatric Mood Disorders - A Free Webinar from the Brain & Behavior Research Foundation
May 06, 2020 09:00 ET
|
Brain & Behavior Research Foundation
New York, May 06, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar “Using Neuroscience to Evaluate and Guide Treatment for Pediatric Mood Disorders” on...
Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)
April 21, 2020 01:15 ET
|
Novartis International AG
New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed...
Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
April 16, 2020 01:15 ET
|
Novartis International AG
Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc and...
University of Minnesota Department of Neuroscience Approved for Funding from ARCS Foundation
April 15, 2020 11:09 ET
|
ARCS Foundation Inc.
LaGrange, GA, April 15, 2020 (GLOBE NEWSWIRE) -- ARCS® Foundation is pleased to announce it has approved adding the Department of Neuroscience within the University of Minnesota Medical School to...
Neuroscience Study Finds Consumers Engage Most with “Hopeful” & Encouraging Messaging about COVID-19
April 09, 2020 07:00 ET
|
Brain Scientific
NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- Brain Scientific Inc. (OTC:BRSF) (“Brain Scientific” or “Company”), a medical device and technology company offering products and solutions related to...